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Approximately 90 dermatologic 
researchers from academia, gov-
ernment, and industry convened in 
October 2008 for the Burden of Skin 
Disease Co-Morbidities Project Launch 
Conference.* The conference, spon-
sored by the Society for Investigative 
Dermatology (SID), was organized by 
Lowell Goldsmith, Senior Scientific 
and Medical Advisor; Becky Minnillo, 
Senior Director, Programs and 
Research; and Dennis Barbour, Chief 
Executive Officer. The overarching goal 
of this conference, which launches a 
multi-year, multidisciplinary project, 
was to facilitate interaction and col-
laboration across multiple clinical and 
basic science disciplines, including 
dermatology, cardiology, oncology, 
psychiatry, epidemiology, and industry. 
Through research presentations, exam-
ination of the existing data resources, 
and group panel discussions, the 
participants were able to identify 
potentially productive interdisciplinary 
collaborations and funding sources. 
SID plans to partner in this effort with 
government, industry, academia, and 
the nonprofit and for-profit health sec-
tors.
For the purposes of this initiative, 
comorbidity refers to the presence 
of skin disease concurrent with one 
or more conditions that occur with 
prevalence higher than chance. In this 
respect, dermatological disease may 
be the cause, an associated risk fac-
tor, or a predictor of comorbidity. The 
simultaneous presence of skin disease 
and a second condition makes the 
study of these conditions complex and 
emphasizes the need for collabora-
tion among experts from several disci-
plines. Associations between skin dis-
ease and cardiovascular disease, skin 
disease and psychiatric disease, and 
adverse skin reactions and toxicity of 
drug therapies, mostly oncology drugs, 
were examined in detail during the 
conference.
In the keynote address, Brian Strom, 
from the University of Pennsylvania, 
described epidemiological approaches 
to studying drug-induced disease. The 
emergence of new classes of therapeu-
tic agents for skin diseases and reac-
tions of new drugs that involve the skin 
made this a cogent keynote subject. 
Pharmacoepidemiology involves the 
study of the use and effects of a drug in 
a population. It is particularly impor-
tant for dermatology because skin reac-
tions are the most common adverse 
drug reactions (ADRs). Premarketing 
drug safety studies yield incomplete 
information about adverse events. 
Postmarketing studies, on the other 
hand, are potentially more powerful; 
however, submission of data for these 
studies has not always been required. 
In fact, these studies commonly arise 
out of crises observed during patient 
use in large and often unintended 
populations. Uniquely, pharmacoepi-
demiology studies are influenced by 
the major role that industry plays as 
well as the interplay among indus-
try and government regulators and 
the enormous public interest in drug 
safety. Results from these studies can 
delineate risk factors for drug-induced 
disease, describe pharma cogenetics, 
suggest mechanisms for molecular 
pharmacoepidemiology, and describe 
drug interactions. In sum, the analy-
sis of pharmacoepidemiologic data is 
critical for understanding the effects 
of drug therapy on patients in the face 
of the inherent problems of the drug 
approval process; however, the lack 
of trained personnel and the difficulty 
in obtaining adequate data pose chal-
lenges to be addressed in the future.
Mark Udey, from the National 
Institutes of Health, talked about 
the systemic signs of skin disease. 
Although it is clear that skin signs fre-
quently reflect systemic disease, it is 
also reasonable to expect that systemic 
signs reflect skin disease. Indeed, iden-
tification of comorbidities can lead 
to improved patient health via early 
intervention or prevention strategies as 
well as to insight into the pathogenesis 
of morbid conditions. As a result, the 
study of comorbidities by dermatolo-
gists is critical. A laundry list of chal-
lenges, however, must be overcome. 
To study a comorbidity, the important 
questions must be well defined in 
order to elicit the necessary data in a 
way that changes medical practices 
for improved health. Interestingly, the 
relevance of these findings may extend 
beyond the condition being studied. 
In addition, the necessary resources 
for these studies must be developed, 
including data sources, partnerships, 
and funding sources. Perhaps most 
importantly, enhanced interaction 
between dermatologists and other 
specialists in the health-care commu-
nity will undoubtedly benefit the study 
of comorbidities and allow derma-
tologists to make a greater impact on 
patient health in general.
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Dermatotoxicity
One of the key areas of interest for 
the study of comorbidity of skin dis-
eases is the effect of drugs on the skin. 
Mario Lacouture, from Northwestern 
University, discussed dermatotox-
icity, including the direct effects of 
drugs on rapidly proliferating cells, 
adverse reactions, and extravasation 
reactions. Dermatotoxicity is a par-
ticularly compelling field of research 
because some 500,000 people will 
undergo chemotherapy and 800,000 
will undergo radiotherapy this year, 
and the most commonly used oncol-
ogy drugs give rise to frequent derma-
tologic toxicities compared with other 
marketed drugs. Indeed, the success of 
the new-generation targeted antican-
cer therapies is often predicted on the 
basis of the accompanying skin toxic-
ity. Dermatotoxicities often seriously 
impact patients’ quality of life and 
may lead to curtailment of treatment. 
Only about 8% of oncologists refer 
patients to dermatologists for these 
issues, although dermatotoxicities 
cause 32% of patients to discontinue 
therapy and an additional 60–76% of 
patients to reduce or interrupt therapy. 
Dermatotoxicities are amenable to 
study and therapy development, and 
at least 24 trials are under way in an 
interdisciplinary setting to address 
these clinical needs.
Edward Cowen, from the National 
Cancer Institute, described a spe-
cific system for examining dermato-
toxicity in the context of comorbid-
ity. Graft-versus-host disease occurs 
in a significant number of allogeneic 
stem cell transplantation patients, 
and in 75–90% of these people, 
the skin is affected. Comorbidities 
include permanent disfigurement, 
pain, pruritus, wound infection, func-
tional limitations, and therapy-asso-
ciated side effects such as infection. 
Corticosteroids are the most effective 
therapy for GVHD, but these bring 
relief to only about 25% of patients. 
This disease is quite difficult to study 
because of its rarity; thus, institutional 
or even multi-institutional, multidis-
ciplinary collaboration is needed. A 
diagnostic instrument for severity and 
a multi-organ approach, complete 
with appropriate specialist referrals, is 
required to gain a better understanding 
of the disease pathogenesis and to 
develop appropriate therapies.
In the dermatotoxicity break-
out session, Charles Bennett, from 
Northwestern University, described 
the Research on Adverse Drug Events 
and Reports project. This postmarket-
ing pharmacovigilance initiative aims 
to detect ADR signals, investigate ADR 
occurrences, analyze these data, and 
disseminate the results. This project is 
important for dermatologists because 
the larger, more comprehensive data 
sets include reports of adverse effects 
by all clinicians, and they may indi-
cate skin effects as merely a “rash” 
without a clinical diagnosis. Other 
registries and data sets that are avail-
able for this type of analysis include 
the United Kingdom’s General Practice 
Research Database, the Food and 
Drug Administration (FDA) Adverse 
Events Reporting System (AERS), and 
MedWatch reports, although these 
data are ill suited for dermatologic 
analysis. Recently, a significant num-
ber of large pharmaceutical com-
panies have combined data on skin 
reactions to facilitate data mining for 
dermatotoxicity. It is difficult to deter-
mine whether the drug was in fact 
the cause of the adverse reaction in 
these patients. Additional studies will 
be necessary to examine this issue in 
detail. Furthermore, studies of derma-
totoxicity with genetic and immune 
susceptibility factors may be of use 
in the identification of patients at 
greater risk for adverse events. Finally, 
increased data availability, more com-
plete reaction accounts, and standard-
ized reporting forms would benefit 
dermatotoxicity research.
Dermatologic–psychiatric disease
Francisco Tausk, from the University 
of Rochester, led a discussion about 
comorbidities in psychiatry and der-
matology. Psychiatric disease influ-
ences the development of skin diseases 
through the effects of stress, depression, 
and anxiety. Not surprisingly, treating 
psychiatric comorbidity improves skin 
disease, and vice versa. For example, 
etanercept has been shown to improve 
depression and psoriasis concurrently. 
Despite these observations and the high 
prevalence of psychiatric and dermato-
logic comorbidities, a lack of common 
instruments for measurement, inad-
equate numbers of trained individuals, 
difficulty in obtaining funding, insuffi-
cient epidemiological data, and a lack 
of integrated treatment facilities prevent 
these conditions from being treated or 
researched effectively and in concert. 
In Europe, however, psychodermatol-
ogy meetings have been well attended, 
educational programs for manage-
ment of skin diseases have been imple-
mented, and a certification program 
has been established. North American 
efforts in psychodermatology may be 
initiated using the European model.
In the breakout session on dermato-
logic-psychiatric disease, contributors 
contrasted the available tools and data 
sources with the need for extensive 
strides in this arena. Alexa Kimball, 
from Harvard University, described the 
importance of quality-of-life assess-
ment. The analysis of quality of life 
with respect to skin disease overlaps 
with psychiatric findings in such areas 
as anxiety, frustration, embarrassment, 
annoyance, and depression, and a sub-
stantial burden on patients with skin 
disease has been observed. Whereas 
comorbid mental illness is typically 
diagnosed by a physician, quality-of-
life issues (particularly appearance) 
are most often reported by the patient. 
Good therapy improves quality of life, 
but it is not yet known whether such 
therapy improves comorbid mental ill-
ness. Researchers need to understand 
the interactions between quality of life 
and comorbid mental illness, develop 
tools for diagnosing psychiatric ill-
ness and assessing improvement in 
trials, and determine how psychiatric 
illness is coded in databases to allow 
researchers access to archived data 
for dermatologic–psychiatric stud-
ies. According to Phillip Harvey, from 
Emory University, neuropsychiatric 
conditions account for 9 of the 10 most 
common causes of disability, whereas 
skin conditions are not reported to be 
a significant cause of disability. The 
reporting of psychiatric symptoms, 
by patients or by physicians using 
standardized scales, may be biased 
according to clinician expertise and 
patient perception and literacy. The 
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determinants of real-world disability 
are a challenge to assess. Interestingly, 
the causal models for dermatological 
conditions suggest different points for 
intervention. For example, does itch-
ing lead to depression, which leads to 
disability, which leads to lower quality 
of life? Or does itching lead to disabil-
ity, depression, and reduced quality of 
life, which are all merely correlated? 
Peter Muehrer, head of the comorbid-
ity program at the National Institute 
of Mental Health, indicated that no 
studies of mental disorders in patients 
with skin disease are currently funded 
through the institute. With this he con-
firmed not only the need for this type 
of research but also the potential avail-
ability of funding for these studies.
Cutaneous–cardiovascular disease
Expanding on the association between 
skin disease and systemic disease, 
Joel Gelfand, from the University of 
Pennsylvania, discussed the apparent 
link between psoriasis and cardiovas-
cular disease (CVD). Psoriasis, which 
affects more than 70 million people, is 
an inflammatory disease with complex 
etiology, and inflammation is known 
to contribute to chronic diseases such 
as atherosclerosis, diabetes, and obe-
sity. The risk of mortality in patients 
with psoriasis is 50% greater than in 
healthy individuals, perhaps because 
of the central role of inflammation in 
the pathogenesis of atherosclerosis 
and myocardial infarction. Psoriasis is 
also associated with additional CVD 
risk factors, including smoking, obe-
sity, dyslipidemia, hypertension, and 
diabetes. Severe psoriasis is associ-
ated with increased risk of myocardial 
infarction and coronary artery disease. 
These associations suggest countless 
areas for investigation.
In the breakout session on cuta-
neous–cardiovascular disease, con-
tributors reexamined the link between 
psoriasis and CVD and discussed data 
needs and potential sources. Both Kevin 
Cooper, from the University Hospital 
at Case Western Reserve University, 
and Eric Yang, from the University of 
North Carolina, discussed the role of 
inflammation in psoriasis and CVD. 
Investigation into whether aggressive 
treatment for psoriasis inflammation 
reduces atherosclerosis and the fre-
quency of myocardial infarction and 
whether aggressive atherosclerosis 
treatment reduces psoriasis symptoms 
is warranted but requires specialized 
expertise, high-quality data, broad and 
unbiased participation, and the partic-
ipation of community-practice physi-
cians. The Case Western collaboration 
between a newly funded Center of 
Research Translation for psoriasis and 
the Murdough Family Psoriasis Center 
is one example of an approach to this 
field of investigation.
Joel Kremer, from the Albany 
Medical College Center for 
Rheumatology, presented infor-
mation about the industry-spon-
sored Consortium of Rheumatology 
Researchers of North America 
(CORRONA) database, which includes 
31,000 patient years of follow-up of 
rheumatoid arthritis, psoriatic arthritis, 
and osteoarthritis patients. The goal 
of this large, long-term database is to 
provide information on the safety and 
efficacy of agents used in the treatment 
of these diseases. Registries such as 
CORRONA and the British Society for 
Rheumatology Biologics Registry are 
a significant challenge in the United 
States, which lacks a centralized medi-
cal record system and is plagued by 
issues related to the Health Insurance 
Portability and Accountability Act, 
selection bias, lack of representation 
of the general population, and under-
represented academic institutions. 
The CORRONA database, however, 
includes thousands of individuals with 
psoriatic arthritis and, despite its inher-
ent limitations, is an excellent source 
of data for studying the associations 
among inflammation, psoriasis, and 
CVD.
The following questions are at the 
top of the anticipated research agenda: 
What is the risk of CVD? How do other 
factors affect this risk? Does aggres-
sive treatment of psoriasis reduce CVD 
risk? Does aggressive treatment of ath-
erosclerosis reduce psoriasis symp-
toms? What are the mechanisms of 
these interactions?
resources for research
Several presenters from academia, 
government, and industry described 
the advantages and limitations of the 
databases and related resources for 
investigating skin disease comorbidi-
ties. According to Robert Lew, from 
the Veterans Administration (VA), 
the VA has resources for dermato-
logic research, including VA study 
design and database resources, the 
Epidemiology Research Information 
Center, a clinical trial coordinating 
center, and the VA core laboratory 
for blood and tissue sample storage. 
These resources include 12 million 
electronic records with an average of 
5 years of follow-up. Outside investi-
gators must collaborate with experts 
within the VA, the population served is 
very selective, and the records are dif-
ficult to abstract. However, this mas-
sive resource is worth exploring, and 
it even offers internal support in medi-
cine, information technology, epide-
miology, and statistics.
The FDA also offers extensive data 
resources for clinical research. The 
clinical safety database is the result 
of premarketing drug safety studies, 
but other, more robust postmarketing 
safety information is also archived. 
Both MedWatch reporting and the 
Adverse Events Reporting System 
reports are available for download-
ing. These sources are especially use-
ful for detecting the signal of unsafe 
reactions, although the data cannot be 
used for prevalence or causality assess-
ments based on the lack of perfect 
reporting by patients and physicians. 
Furthermore, the National Cancer 
Institute sponsors the Surveillance 
Epidemiology and End Results 
Program, which, since 1973, has pro-
vided information on incidence, sur-
vival, and prevalence from specific 
geographic areas representing 26% of 
the US population. The US Centers for 
Disease Control and Prevention also 
offers online databases and surveil-
lance systems that can be tapped by 
outside researchers.
Private sources of data, although 
more difficult to access, are also avail-
able. Maryam Asgari, from Kaiser 
Permanente, described the Kaiser 
Research Database, which includes 
electronic data records from 1968 
onward for 8.5 million patients seen 
by almost 13,000 physicians. This 
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large data set includes patient demo-
graphics, diagnoses, procedures, labs, 
pharmacy data, inpatient admissions, 
electronic pathology, and addi-
tional details such as occupation, 
family history, and body mass index. 
These data, in particular, lend them-
selves to research on dermatotoxicity 
because of the electronic pharmacy 
and diagnoses records. Research is 
being carried out on dermatology 
comor bidities within Kaiser; however, 
additional studies with collaborating 
outside investigators are limited by the 
this HMO’s small research staff.
In addition to these broader gen-
eralized databases, pharmaceutical 
companies and academic researchers 
have developed their own target-
ed data sets. For example, Stephen 
Rozzo, from Abbott, described the 
HUMIRA registry, which includes 
data on 6,000 psoriasis patients. This 
postmarketing multinational commit-
ment is focused on archiving adverse 
events to evaluate the long-term safety 
and effectiveness of adalimumab. This 
registry offers data regarding safety, 
work productivity, activity impair-
ment, dermatologic life quality index, 
and patient global assessment. Marc 
Chevrier, from Centocor, described 
the current use of biologic cohort 
studies to address the difficulties in 
dermatology registries, such as prima-
ry care of patients at sites other than 
the site of the dermatologist, finding 
rare events requiring a large number 
of patients, and the typical simplified 
data set structure used for consolida-
tion of data from multiple sources. 
Thus, multicenter biologic observa-
tional cohort studies can be performed 
to examine therapies in the actual 
clinical setting, incorporate compara-
tor cohorts, and optimize the abil-
ity for in-depth analysis of particular 
contexts. Effectiveness, safety, prod-
uct, and disease registries are options 
for addressing specific data needs. At 
the University of Texas MD Anderson 
Cancer Center, Madeline Duvic is 
spearheading one such endeavor, the 
National Alopecia Areata Registry, 
to investigate familial genetic asso-
ciations and quality-of-life issues. 
It involves participation in a Web-
based, patient-friendly registry at five 
institutions, followed by a physical 
exam to confirm alopecia areata. Sera 
and DNA samples are taken for analy-
sis. This registry of 6,500 patients has 
enabled confirmation of association 
with HLA alleles, studies of cytokine 
profiles, and a case–control study on 
autoimmunity.
Conclusions
Comorbidity as a concept is clearly 
not well defined, and the term can 
be used for causes, effects, and con-
founders. The current research agenda 
aims to gain a mechanistic under-
standing of drug reactions and their 
relationship to host susceptibility 
factors, a mechanistic understanding 
of the effect of skin diseases on the 
psyche and of the psyche on skin dis-
eases, and a mechanistic understand-
ing of the effect of inflammatory skin 
diseases on various organ systems 
such as the cardiovascular system, 
the central nervous system, and the 
liver. Investigation into these broad 
areas will require extensive collabo-
ration among individual researchers 
in multiple disciplines, and these 
collaborations must include a host of 
institutions to ensure success.
Training in statistics and pharma-
coepidemiology for junior faculty and 
residents is especially important. The 
American Skin Association offers indi-
vidual fellowships in epidemiology 
for dermatology residents, and entry 
level grants are available; however, 
funding for senior level work in these 
fields has historically been difficult 
to obtain. Increased funding for indi-
vidual investigators and collaborative 
efforts in these areas would advance 
this line of investigation.
In a final analysis of the meeting, 
Lowell Goldsmith, from the University 
of North Carolina, and Brian Strom 
summarized the next logical steps to 
enable investigation of comorbidities 
and to facilitate interdisciplinary col-
laborations. Importantly, the questions 
should be focused and well defined, 
and the necessary data should then be 
collected and/or databases queried. 
Many registries and databases are 
available, although each has its limi-
tations and inherent biases that must 
be acknowledged. The importance of 
multidisciplinary teams of both clini-
cians and methodologists is unmis-
takable. Each brings unique expertise 
and perspective, essential for asking 
the right questions and formulating 
the correct methodologies.
To promote the investigation of 
comorbidities of skin disease, the 
SID will disseminate the information 
discussed at this conference through 
specialty journals and other media 
sources as well as Web-based slide 
presentations and webinars. Online 
resources will include a database of 
comorbidities publications; develop-
ment of communications forums for 
meeting attendees, junior faculty, and 
residents; links to participants’ names, 
affiliations, and research interests; and 
information about laboratories that 
wish to be involved in this cutting-
edge research. In addition, a separate 
Co-Morbidities Symposium will be 
held at the 2009 Annual SID Meeting 
in Montreal. Overall, the success of 
this SID project will depend on how 
effective this group can be in facilitat-
ing the creation of research teams that 
span a variety of disciplines.
*The Burden of Skin Disease Co-Morbidities 
Project Launch Conference was held at 
the Bethesda North Marriott Hotel and 
Conference Center, Bethesda, Maryland, on 
15–16 October 2008. The conference was 
sponsored by the Society for Investigative 
Dermatology.
